A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer
| Autor: | Joel Alderson, Nathaniel A Parker, Khalil Choucair, Jeremy M Deutsch, Ammar Al-Obaidi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Programmed cell death
medicine.medical_treatment Cardiology immune-checkpoint inhibitors 030204 cardiovascular system & hematology Autoimmune heart disease pd-1 inhibitors 03 medical and health sciences 0302 clinical medicine Immune system Cancer immunotherapy Internal Medicine Medicine Cytotoxic T cell ctla-4 inhibitors autoimmune cardiotoxicity Adverse effect cancer immunotherapy business.industry General Engineering Immunotherapy medicine.disease autoimmune myocarditis metastatic non-small cell lung cancer Oncology autoimmune heart disease Heart failure Cancer research business 030217 neurology & neurosurgery life threatening |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.8093 |
| Popis: | Inhibitors of cytotoxic T-lymphocyte-associated antigen-4, programmed cell death protein-1, and programmed death-ligand 1 have been shown to produce significant antitumor activity in multiple malignancies, and have become essential oncology standard-of-care therapies. Despite their success, the checkpoint inhibitors’ ability to amplify the immune system response against tumor cells has been associated with a unique panel of side effects known as immune-related adverse events. The involvement of the myocardium has been reported previously, but it’s remarkably uncommon. Even more noteworthy is that secondary autoimmune myocarditis and heart failure due to these medications are typically fatal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|